Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?
- PMID: 20735441
- PMCID: PMC2990927
- DOI: 10.1111/j.1365-2249.2010.04223.x
Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?
Abstract
Guillain-Barré syndrome (GBS) is an acute, usually monophasic, disorder of the peripheral nervous system that is assumed to be of immune-mediated pathogenesis. However, several clinical features and experimental findings of GBS are uncharacteristic for an immune-mediated disorder and set this condition apart from other disorders with a putative immune-mediated pathogenesis. These features include, among others, the monophasic nature of GBS, the lack of response to immunosuppressive (unlike immunomodulatory) therapy, the absence of a typical association with immunogenetic background and the inability to establish a valid and relevant animal model. We suggest a comprehensive hypothesis for the pathogenesis of GBS that is based on the assumption that the condition is due to a transient (or occasionally chronic) immune deficiency, as in most cases GBS follows an infection with pathogens known to induce immunosuppression. Such infections may be followed by breakdown of immune tolerance and induction of an immune attack on peripheral nerves. Mounting of the immune-mediated assault might be triggered either by the same infective pathogen or by secondary infection. Clearance of the infection and resumption of a normal immune response and tolerance eventually terminate the immune-mediated damage to the peripheral nerves and enable recovery. This hypothesis assumes that the entire sequence of events that culminates in GBS is due to transient exogenous factors and excludes a significant role for inherent host susceptibility, which explains the monophasic nature of the disorder.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.
Similar articles
-
Autoimmunity and cytokines in Guillain-Barré syndrome revisited: review of pathomechanisms with an eye on therapeutic options.Eur Cytokine Netw. 2019 Mar 1;30(1):1-14. doi: 10.1684/ecn.2019.0424. Eur Cytokine Netw. 2019. PMID: 31074417 Review.
-
Guillain-barré syndrome: modern theories of etiology.Curr Allergy Asthma Rep. 2011 Jun;11(3):197-204. doi: 10.1007/s11882-011-0190-y. Curr Allergy Asthma Rep. 2011. PMID: 21451970 Review.
-
Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome.Mediators Inflamm. 2014;2014:758639. doi: 10.1155/2014/758639. Epub 2014 Sep 22. Mediators Inflamm. 2014. PMID: 25614713 Free PMC article. Review.
-
Guillain-Barré syndrome--a classical autoimmune disease triggered by infection or vaccination.Clin Rev Allergy Immunol. 2012 Apr;42(2):121-30. doi: 10.1007/s12016-010-8213-3. Clin Rev Allergy Immunol. 2012. PMID: 20890797 Review.
-
Zika autoimmunity and Guillain-Barré syndrome.Curr Opin Rheumatol. 2019 Sep;31(5):484-487. doi: 10.1097/BOR.0000000000000629. Curr Opin Rheumatol. 2019. PMID: 31246623 Review.
Cited by
-
Intracerebral haemorrhage and Guillain-Barré syndrome: an exploration of potential pathophysiology.BMJ Case Rep. 2021 Aug 3;14(8):e243245. doi: 10.1136/bcr-2021-243245. BMJ Case Rep. 2021. PMID: 34344649 Free PMC article.
-
Are Cerebrospinal Fluid Protein Levels and Plasma Neutrophil/Lymphocyte Ratio Associated with Prognosis of Guillain Barré Syndrome?Neurol Int. 2017 Jun 23;9(2):7032. doi: 10.4081/ni.2017.7032. eCollection 2017 Jun 23. Neurol Int. 2017. PMID: 28713530 Free PMC article.
-
Guillain-Barré syndrome and severe infection following chemotherapy for peripheral T-cell lymphoma: A case report.Oncol Lett. 2014 Dec;8(6):2695-2698. doi: 10.3892/ol.2014.2541. Epub 2014 Sep 16. Oncol Lett. 2014. PMID: 25360176 Free PMC article.
-
Guillain-Barré Syndrome Following Lung Adenocarcinoma Surgery: A Case Report and Literature Review.Am J Case Rep. 2024 Jul 2;25:e944035. doi: 10.12659/AJCR.944035. Am J Case Rep. 2024. PMID: 38954599 Free PMC article. Review.
-
Staphylococcus epidermidis Bacteremia in an Older Patient With Guillain-Barré Syndrome With Fever of Unknown Origin: A Case Report.Cureus. 2023 Sep 25;15(9):e45940. doi: 10.7759/cureus.45940. eCollection 2023 Sep. Cureus. 2023. PMID: 37885527 Free PMC article.
References
-
- Hughes RA, Cornblath DR. Guillain–Barré syndrome. Lancet. 2005;366:1653–66. - PubMed
-
- Willison HJ. The immunobiology of Guillain–Barré syndromes. J Peripher Nerv Syst. 2005;10:94–112. - PubMed
-
- Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher–Bickerstaff syndrome) J Neuroimmunol. 2009;215:1–9. - PubMed
-
- van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain–Barre syndrome. Lancet Neurol. 2008;7:939–50. - PubMed
-
- Vucic S, Kiernan MC, Cornblath DR. Guillain–Barre syndrome: an update. J Clin Neurosci. 2009;16:733–41. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical